Lenka Sedlaříková

1.4k total citations
33 papers, 1.0k citations indexed

About

Lenka Sedlaříková is a scholar working on Hematology, Molecular Biology and Cancer Research. According to data from OpenAlex, Lenka Sedlaříková has authored 33 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Hematology, 18 papers in Molecular Biology and 17 papers in Cancer Research. Recurrent topics in Lenka Sedlaříková's work include Multiple Myeloma Research and Treatments (17 papers), Cancer Genomics and Diagnostics (7 papers) and MicroRNA in disease regulation (6 papers). Lenka Sedlaříková is often cited by papers focused on Multiple Myeloma Research and Treatments (17 papers), Cancer Genomics and Diagnostics (7 papers) and MicroRNA in disease regulation (6 papers). Lenka Sedlaříková collaborates with scholars based in Czechia, Switzerland and Italy. Lenka Sedlaříková's co-authors include Sabina Ševčı́ková, Roman Hájek, Lenka Kubiczková, Luděk Pour, Eva Kriegová, Tomáš Papajík, Anna Petráčková, Luděk Pour, Lenka Bešše and Martina Almáši and has published in prestigious journals such as Blood, PLoS ONE and British Journal of Cancer.

In The Last Decade

Lenka Sedlaříková

33 papers receiving 1.0k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Lenka Sedlaříková Czechia 13 616 290 289 277 130 33 1.0k
Bin Fan United States 17 448 0.7× 262 0.9× 218 0.8× 248 0.9× 79 0.6× 52 1.0k
Maria Grazia di Iasio Italy 18 686 1.1× 127 0.4× 205 0.7× 415 1.5× 73 0.6× 28 1.1k
Jens Hasskarl United States 20 587 1.0× 137 0.5× 146 0.5× 503 1.8× 129 1.0× 42 1.2k
Lenka Kubiczková Czechia 11 479 0.8× 193 0.7× 159 0.6× 217 0.8× 60 0.5× 17 782
Sabine Blum Switzerland 17 420 0.7× 297 1.0× 141 0.5× 214 0.8× 47 0.4× 59 976
Sheila N.J. Sait United States 20 510 0.8× 511 1.8× 192 0.7× 334 1.2× 178 1.4× 72 1.2k
Lin Fu China 20 959 1.6× 359 1.2× 538 1.9× 211 0.8× 54 0.4× 96 1.4k
Gernot Keyszer Germany 18 441 0.7× 184 0.6× 354 1.2× 310 1.1× 83 0.6× 24 1.5k
Jiantao Shi China 15 749 1.2× 302 1.0× 246 0.9× 125 0.5× 43 0.3× 37 1.0k
Hind Medyouf Germany 13 526 0.9× 247 0.9× 157 0.5× 298 1.1× 56 0.4× 23 976

Countries citing papers authored by Lenka Sedlaříková

Since Specialization
Citations

This map shows the geographic impact of Lenka Sedlaříková's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lenka Sedlaříková with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lenka Sedlaříková more than expected).

Fields of papers citing papers by Lenka Sedlaříková

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lenka Sedlaříková. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lenka Sedlaříková. The network helps show where Lenka Sedlaříková may publish in the future.

Co-authorship network of co-authors of Lenka Sedlaříková

This figure shows the co-authorship network connecting the top 25 collaborators of Lenka Sedlaříková. A scholar is included among the top collaborators of Lenka Sedlaříková based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lenka Sedlaříková. Lenka Sedlaříková is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Sedlaříková, Lenka, Marianne Kraus, Nicol Straková, et al.. (2024). HIV-protease inhibitors potentiate the activity of carfilzomib in triple-negative breast cancer. British Journal of Cancer. 131(5). 918–930. 2 indexed citations
2.
Sedlaříková, Lenka, et al.. (2020). Resistance-Associated Mutations in Chronic Lymphocytic Leukemia Patients Treated With Novel Agents. Frontiers in Oncology. 10. 894–894. 46 indexed citations
3.
Petráčková, Anna, et al.. (2019). Standardization of Sequencing Coverage Depth in NGS: Recommendation for Detection of Clonal and Subclonal Mutations in Cancer Diagnostics. Frontiers in Oncology. 9. 851–851. 82 indexed citations
4.
Sedlaříková, Lenka, Lenka Bešše, Lucie Říhová, et al.. (2019). Dynamics of tumor‐specific cfDNA in response to therapy in multiple myeloma patients. European Journal Of Haematology. 104(3). 190–197. 25 indexed citations
5.
Gregorová, Jana, Lenka Sedlaříková, Martina Almáši, et al.. (2018). Tumor Specific cfDNA Predicts Treatment Response of Multiple Myeloma Patients. Blood. 132(Supplement 1). 3188–3188. 1 indexed citations
6.
Abt, Dominik, Andrej Bešše, Lenka Sedlaříková, et al.. (2017). Improving the efficacy of proteasome inhibitors in the treatment of renal cell carcinoma by combination with the human immunodeficiency virus ( HIV )‐protease inhibitors lopinavir or nelfinavir. British Journal of Urology. 121(4). 600–609. 11 indexed citations
7.
Sedlaříková, Lenka, Lenka Radová, Jiří Jarkovský, et al.. (2017). Deregulated expression of long non‐coding RNA UCA1 in multiple myeloma. European Journal Of Haematology. 99(3). 223–233. 39 indexed citations
8.
Sedlaříková, Lenka, Lenka Radová, Martina Almáši, et al.. (2016). Deregulated Expression of Long Non-Coding RNAs UCA1, NEAT1 and BDNF-As in Multiple Myeloma. Blood. 128(22). 2073–2073. 1 indexed citations
9.
Bešše, Lenka, Lenka Sedlaříková, Henrieta Grešlíková, et al.. (2015). Cytogenetics in multiple myeloma patients progressing into extramedullary disease. European Journal Of Haematology. 97(1). 93–100. 41 indexed citations
10.
Ševčı́ková, Sabina, Lenka Bešše, Lenka Sedlaříková, et al.. (2015). Extramedullary relapse of multiple myeloma defined as the highest risk group based on deregulated gene expression data. Biomedical Papers. 159(2). 288–293. 12 indexed citations
11.
Sedlaříková, Lenka, et al.. (2015). Circulating microRNA as Biomarkers in Hematological Malignancies. Proceedings of the Fourth International Symposium on Polarization Phenomena in Nuclear Reactions. 106. 123–138. 4 indexed citations
12.
Bešše, Lenka, Lenka Sedlaříková, Fedor Kryukov, et al.. (2015). Circulating Serum MicroRNA-130a as a Novel Putative Marker of Extramedullary Myeloma. PLoS ONE. 10(9). e0137294–e0137294. 18 indexed citations
13.
Sedlaříková, Lenka, et al.. (2015). Potential of Cell-free Circulating DNA in Diagnosis of Cancer. Klinicka onkologie. 28(4). 251–259. 2 indexed citations
14.
Kubiczková, Lenka, et al.. (2014). The miR-29 family in hematological malignancies. Biomedical Papers. 159(2). 184–191. 13 indexed citations
15.
Sedlaříková, Lenka, Fedor Kryukov, Lenka Radová, et al.. (2014). Circulating Mir-130a in Multiple Myeloma and Extramedullary Myeloma Patients. Blood. 124(21). 2043–2043. 4 indexed citations
16.
Bešše, Lenka, et al.. (2014). Cereblon – a New Target of Therapy in the Treatment of Multiple Myeloma. Klinicka onkologie. 27(5). 326–330. 2 indexed citations
17.
Kubiczková, Lenka, et al.. (2013). Proteasome Inhibitors in Treatment of Multiple Myeloma. Klinicka onkologie. 26(1). 11–18. 2 indexed citations
18.
Bešše, Lenka, et al.. (2013). Degradation of Proteins by Ubiquitin-Proteasome Pathway. Klinicka onkologie. 26(4). 251–256. 2 indexed citations
19.
Sedlaříková, Lenka, Lenka Kubiczková, Sabina Ševčı́ková, & Roman Hájek. (2012). Mechanism of immunomodulatory drugs in multiple myeloma. Leukemia Research. 36(10). 1218–1224. 22 indexed citations
20.
Kubiczková, Lenka, Lenka Sedlaříková, Roman Hájek, & Sabina Ševčı́ková. (2012). TGF-β – an excellent servant but a bad master. Journal of Translational Medicine. 10(1). 183–183. 407 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Bin Fan Breakdown of academic impact, for papers by Maria Grazia di Iasio Breakdown of academic impact, for papers by Jens Hasskarl Breakdown of academic impact, for papers by Lenka Kubiczková Breakdown of academic impact, for papers by Sabine Blum Breakdown of academic impact, for papers by Sheila N.J. Sait Breakdown of academic impact, for papers by Lin Fu Breakdown of academic impact, for papers by Gernot Keyszer Breakdown of academic impact, for papers by Jiantao Shi Breakdown of academic impact, for papers by Hind Medyouf
Rankless by CCL
2026